161 related articles for article (PubMed ID: 15837754)
1. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.
Dai G; Chan KK; Liu S; Hoyt D; Whitman S; Klisovic M; Shen T; Caligiuri MA; Byrd J; Grever M; Marcucci G
Clin Cancer Res; 2005 Apr; 11(8):2998-3008. PubMed ID: 15837754
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Marcucci G; Stock W; Dai G; Klisovic RB; Liu S; Klisovic MI; Blum W; Kefauver C; Sher DA; Green M; Moran M; Maharry K; Novick S; Bloomfield CD; Zwiebel JA; Larson RA; Grever MR; Chan KK; Byrd JC
J Clin Oncol; 2005 May; 23(15):3404-11. PubMed ID: 15824414
[TBL] [Abstract][Full Text] [Related]
3. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
[TBL] [Abstract][Full Text] [Related]
4. Cationic lipids enhanced cellular uptake and activity of bcl-2 antisense oligodeoxynucleotide G3139 in HL-60 cells.
Zhu YG; Zhuo GS; Chen ZZ; Chen XC
Acta Pharmacol Sin; 2001 Nov; 22(11):1007-12. PubMed ID: 11749792
[TBL] [Abstract][Full Text] [Related]
5. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
[TBL] [Abstract][Full Text] [Related]
6. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
[TBL] [Abstract][Full Text] [Related]
8. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line.
Joyner DE; Albritton KH; Bastar JD; Randall RL
J Orthop Res; 2006 Mar; 24(3):474-80. PubMed ID: 16450387
[TBL] [Abstract][Full Text] [Related]
9. [Oligonucleotide uptake in hematological tumor cells is related to cellular species and proliferation].
Zhu YG; Zhuo GS; Chen ZZ; Chen XC
Yao Xue Xue Bao; 2003 Jun; 38(6):401-4. PubMed ID: 14513795
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA
Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM
Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680
[TBL] [Abstract][Full Text] [Related]
12. Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature.
Anderson EM; Miller P; Ilsley D; Marshall W; Khvorova A; Stein CA; Benimetskaya L
Cancer Gene Ther; 2006 Apr; 13(4):406-14. PubMed ID: 16195754
[TBL] [Abstract][Full Text] [Related]
13. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes.
Chiu SJ; Liu S; Perrotti D; Marcucci G; Lee RJ
J Control Release; 2006 May; 112(2):199-207. PubMed ID: 16564596
[TBL] [Abstract][Full Text] [Related]
14. Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma.
Benimetskaya L; Wittenberger T; Stein CA; Hofmann HP; Weller C; Lai JC; Miller P; Gekeler V
Clin Cancer Res; 2004 Jun; 10(11):3678-88. PubMed ID: 15173074
[TBL] [Abstract][Full Text] [Related]
15. Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry.
Dai G; Wei X; Liu Z; Liu S; Marcucci G; Chan KK
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Oct; 825(2):201-13. PubMed ID: 16111926
[TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis by G3139 in melanoma cells.
Benimetskaya L; Lai JC; Khvorova A; Wu S; Miller P; Stein CA
Ann N Y Acad Sci; 2005 Nov; 1058():235-45. PubMed ID: 16394140
[TBL] [Abstract][Full Text] [Related]
17. A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices.
Wei X; Dai G; Marcucci G; Liu Z; Hoyt D; Blum W; Chan KK
Pharm Res; 2006 Jun; 23(6):1251-64. PubMed ID: 16718617
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
Marcucci G; Byrd JC; Dai G; Klisovic MI; Kourlas PJ; Young DC; Cataland SR; Fisher DB; Lucas D; Chan KK; Porcu P; Lin ZP; Farag SF; Frankel SR; Zwiebel JA; Kraut EH; Balcerzak SP; Bloomfield CD; Grever MR; Caligiuri MA
Blood; 2003 Jan; 101(2):425-32. PubMed ID: 12393493
[TBL] [Abstract][Full Text] [Related]
19. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
Frankel SR
Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
[TBL] [Abstract][Full Text] [Related]
20. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
